Multiple Sclerosis and Related Disorders

REPAIR-MS and REPAIR-PD: tackling disease progression with gold nanocrystals 8:23
REPAIR-MS and REPAIR-PD: tackling disease progression with gold nanocrystals
Robert Glanzman • 13 Oct 2021
Updates on RADIUS-R & RADIUS-P: elezanumab for patients with relapsing and progressive forms of MS 4:34
Updates on RADIUS-R & RADIUS-P: elezanumab for patients with relapsing and progressive forms of MS
Bruce Cree • 21 Oct 2021
Using virtual placebo to assess long-term effect of siponimod on disability progression in SPMS 3:57
Using virtual placebo to assess long-term effect of siponimod on disability progression in SPMS
Bruce Cree • 21 Oct 2021
Validating a 3D synthetic MRI method for myelin measurement 5:32
Validating a 3D synthetic MRI method for myelin measurement
Russell Ouellette • 14 Oct 2021
A score to predict treatment response in pediatric patients with multiple sclerosis 3:26
A score to predict treatment response in pediatric patients with multiple sclerosis
Ermelinda De Meo • 27 Oct 2021
Higher repair capability in early-onset vs late-onset pediatric multiple sclerosis 2:18
Higher repair capability in early-onset vs late-onset pediatric multiple sclerosis
Ermelinda De Meo • 27 Oct 2021
Autoreactive T-cell responses in multiple sclerosis: unanswered questions 2:14
Autoreactive T-cell responses in multiple sclerosis: unanswered questions
Olivia Thomas • 21 Oct 2021
Molecular imaging of myelin: the promise of PET 11:40
Molecular imaging of myelin: the promise of PET
Russell Ouellette • 14 Oct 2021
The protective role of BDNF Val66Met against hippocampal atrophy and cognitive impairment in MS 3:18
The protective role of BDNF Val66Met against hippocampal atrophy and cognitive impairment in MS
Ermelinda De Meo • 27 Oct 2021
Updates on N-MOmentum: inebilizumab versus placebo in patients with NMOSD 2:44
Updates on N-MOmentum: inebilizumab versus placebo in patients with NMOSD
Bruce Cree • 21 Oct 2021
Recent evidence for subclinical disease activity in NMOSD 6:38
Recent evidence for subclinical disease activity in NMOSD
Bruce Cree • 21 Oct 2021
Similarities between the gut microbiome in Parkinson’s disease & MS 0:46
Similarities between the gut microbiome in Parkinson’s disease & MS
Paul Wilmes • 5 Oct 2021
PREVENT study: eculizumab in AQP4-IgG-positive NMOSD 5:10
PREVENT study: eculizumab in AQP4-IgG-positive NMOSD
Kazuo Fujihara • 4 Oct 2021
Novel treatment strategies for NMOSD 1:21
Novel treatment strategies for NMOSD
Kazuo Fujihara • 4 Oct 2021
Symptomatic treatment of NMOSD 2:24
Symptomatic treatment of NMOSD
Kazuo Fujihara • 4 Oct 2021
Diagnostic criteria and treatment updates for NMOSD 5:44
Diagnostic criteria and treatment updates for NMOSD
Kazuo Fujihara • 4 Oct 2021
The content of VJNeurology is intended for healthcare professionals